^gXZX�CH�20�z½�� �u�f� t�J= Macquarie Investor Update May 2020. If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.Registration for this event is available only to Eureka Report members. 0000005669 00000 n This may not include all funds available for retail investment in Australia.
Mobile phone number is required. The PolyNovo share price zoomed as much as 31% higher to $2.20 in early trade. The Directors of PolyNovo Limited (PolyNovo) present the Directors’ Report, together with the Financial Report, of the Company and its controlled entities (the Group) for the year ended 30 June 2016 and the related Auditor’s Report. Roadmap & Annual Reports; Opportunities with TLA; Student Opportunities; Job Opportunities; Resources; Resources & Documents; Search Technologies; You are here. %PDF-1.7 %���� Their development program covers Breast Sling, Hernia, and Orthopedic applications. Posts navigation. 0000010462 00000 n The Company reported a net loss after income tax of $2.42m (2018 $1.92m).
A text message with your verification code was just sent to {{user.DayPhone}}We cannot send you a code via SMS to {{user.DayPhone}}We'll send you a text message with a verification code to start your free {{ '2' == '1' ? 0000034379 00000 n 0000008022 00000 n 6 PolyNovo Limited Annual Report 2017. We look forward to helping you on your financial journey.You now have access to Intelligent Investor Free Insights. Investor Presentation. Only funds with > three year returns were included in any fee comparison, and were compared to Morningstar's nominated benchmark.
0000053051 00000 n does not include fees charged within any ETF held in this portfolio, estimated to be approximately 0.18% (indirect cost ratio). %%EOF 0000018025 00000 n
0000009382 00000 n 2016 Annual Report.
407 0 obj <> endobj xref 407 52 0000000016 00000 n h��UkLSg�z/��:& � cRnӬe�*"�J#� FY 2016 Annual Report. PolyNovo Half-year report 15 February 2018. h��WKlW}��x�%1��8���R�b���`C�Cl�|���� !� �؆� hA��~��hQU��V�DW�*�Vj���X R%#�`��Ǝ=c����>�Rf�{�}�1BH�u�R"#*/#�S#%R����Y��i~��}�˦�V�VC��7����[ �*��/�=��h'�W���ʦ�����C��������%���]7�Ѫg���Ǿ�>�}�C�y�M�}�@�C���Ru������@��ؓE�� �}�JK>I\��nj�X߮OZ>������с�ñ��q�F�̧����}�Y��[N�sX��F�FM�� 7�:��i���kV�m^��a E��f6�'��i jj-���{SkK[w�/����x]�^�9� 2019 Annual Report. Older posts. 0000005764 00000 n 0000005152 00000 n PolyNovo Limited (‘Company’ or ‘PolyNovo’) today announced the half year results for the period ending 31 December 2018. AGM Presentation. PolyNovo Limited FY 19 Annual Report Brokers’ Presentation 22 August 2019 ASX: PNV. 0000036533 00000 n 0000036608 00000 n 0000023562 00000 n The reduced loss reflects the significant growth … Sales of goods revenue was $1.747 million up $1.610 million from the prior year’s $136,896. 2017 Annual Report . %PDF-1.7 %���� Healthcare … 0000009531 00000 n The net loss after tax of $3.190 million for FY19 was a decrease of $2.784 million from the prior year’s $5.974 million. 0000003196 00000 n Mobile phone number is invalid. 0000008193 00000 n
PolyNovo Half-Year Reports February 2017. 0000010090 00000 n The company plans to use synthetic biomaterials to create new valve replacement … 0000029835 00000 n Email is required. endstream endobj startxref Annual Report. Half Year Results Feb 2016. 0000017638 00000 n Polynovo Limited (PNV) is an Australian based medical device company that designs, develops and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology.
Mr Max Johnston Non-executive Director Mr Johnston was appointed a Non-executive Director on 13 May 2014. Their development program covers Breast Sling, Hernia, and Orthopedic applications. While this analysis focuses on total compensation, it’s worth noting the salary is lower, valued at AU$265k. Annual Report. endstream endobj 566 0 obj <>/Metadata 70 0 R/Pages 563 0 R/StructTreeRoot 106 0 R/Type/Catalog/ViewerPreferences 577 0 R>> endobj 567 0 obj <>/MediaBox[0 0 720 405]/Parent 563 0 R/Resources<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/XObject<>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 568 0 obj <>stream 0000052510 00000 n You should consider the product disclosure statement before making a decision about a product.
The peer comparison figures have been sourced from Morningstar data and is therefore limited to the funds and investment products included in their database. Please refer to our IMPORTANT: This information is general financial product advice only and you should consider the relevant product disclosure statement (PDS) or seek professional advice before making any investment decision. 0000024242 00000 n $0.10 0000011644 00000 n 2018 Annual Report. Email is required. h�bbd```b``���A$S"X����� �ID:t I��HٱH�q������tl#E���k� /�